ArticleVaccines2022

Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy.

Zsolt Matula et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.